Island Pharmaceuticals Ltd
ASX:ILA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Island Pharmaceuticals Ltd
Cash from Operating Activities
Island Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Island Pharmaceuticals Ltd
ASX:ILA
|
Cash from Operating Activities
-AU$2.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Cash from Operating Activities
-AU$2.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Cash from Operating Activities
AU$17.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Cash from Operating Activities
AU$125.4m
|
CAGR 3-Years
227%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Cash from Operating Activities
-AU$54.8m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Cash from Operating Activities
AU$16.4m
|
CAGR 3-Years
81%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
Island Pharmaceuticals Ltd
Glance View
Island Pharmaceuticals Ltd. is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-04-13. The firm focuses on developing preventative or therapeutic drugs for viral infections. Its lead product candidate ISLA-101, is a drug developed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Its ISLA-101 is an antiviral oral drug to treat mosquito-borne viruses and is in Phase II of the clinical program.
See Also
What is Island Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
-2.8m
AUD
Based on the financial report for Jun 30, 2025, Island Pharmaceuticals Ltd's Cash from Operating Activities amounts to -2.8m AUD.
What is Island Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-14%
Over the last year, the Cash from Operating Activities growth was 13%. The average annual Cash from Operating Activities growth rates for Island Pharmaceuticals Ltd have been -14% over the past three years .
